Dr. Guo has conducted biomedical research for more than 15 years, with excellent research experience in cell phenotypic regulation, gene transcriptional regulation, screening of signaling pathways/factors that mediate gene function, and generation of conditional knockout mice to examine the biological function of genes in specific tissues using animal models. Dr. Guo received her PhD in Physiology and Pharmacology at the University of Georgia in 2014. After graduation, she worked as a postdoctoral fellow and scientist in the Department of Physiology and Pharmacology at the University of Georgia. In 2019, Dr. Guo joined the University of Texas Health Science Center at Tyler as an Assistant Professor in the Department of Cellular and Molecular Biology. She has published over 30 peer-reviewed papers in journals such as Circulation Research and Journal of Hepatology as the first author. Dr. Guo is also an active member of the American Heart Association (AHA) since 2012. Dr. Guo’s research program has been continuously funded by the American Heart Association (AHA) and the National Institutes of Health (NIH) since 2012.

Education & Training

Assistant Research Scientist, The University of Georgia, 2019
Postdoctoral Fellow, The University of Georgia, 2018
PhD, The University of Georgia, Physiology and Pharmacology, 2014
MS, Fudan University, Molecular Epidemiology of Tumor, China, 2007
BS, Jining Medical College, Preventive Medicine, China, 2004

Research Interest

Dr. Guo’s research broadly focuses on understanding the novel molecules and mechanisms important for cardiovascular disease and/or metabolic disease development. These molecules may contribute to the prevention and/or generation of therapeutics of these human diseases. Specifically, we study 1) the vascular smooth muscle cell (SMC), endothelial cell (EC), and immune cell phenotypic change during the cardiovascular disease development including atherosclerosis, abdominal aortic aneurysm (AAA), hypertension, restenosis and so on; 2) the adipocyte, liver cell, and immune cell phenotypic change during the metabolic disease development including obesity, diabetes, hepatic steatosis, and related complications. Our laboratory uses multiple, cutting-edge approaches to identify novel targets and develop gene/cell-based therapeutics to treat these human problems.

Vascular smooth muscle cell differentiation
Vascular smooth muscle cell phenotypic modulation in vascular remodeling
Endothelial cell inflammation and macrophage activation in atherosclerosis
Epithelial-mesenchymal transition (EMT) in disease development
Metabolic diseases including obesity, diabetes, and hepatic steatosis

Publication Highlights

Guo X, Li FF, Xu Z, Yin A, Yin H, Li C, and Chen SY. (2017). DOCK2 deficiency mitigates HFD-induced obesity by reducing adipose tissue inflammation and increasing energy expenditure. J Lipid Res. Sep;58(9):1777-1784.

Guo X, Shi N, Cui XB, Wang JN, Fukui Y, and Chen SY. (2015). Dedicator of cytokinesis 2, a novel regulator for smooth muscle phenotypic modulation and vascular remodeling. Circ Res. 116(10):e71-80.

Shi N, Guo X, Chen SY. (2014). Olfactomedin 2, a novel regulator for transforming growth factor-β-induced smooth muscle differentiation of human embryonic stem cell-derived mesenchymal cells. Mol Biol Cell. 25 (25): 4106-14.